Steven M. Finegan - Concepedia

Author

Steven M. Finegan

Pfizer (United States)

Also Known As

Finegan, S.M., S FINEGAN, S. M. FINEGAN, S. M. Finegan, S.M. Finegan, Steven Finegan, Steven M. Finegan

Publications

482

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)

About

Steven M. Finegan is an author at Pfizer (United States) specializing in antimicrobial resistance, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	288
2	Natural Sciences	3	3	115
3	Health Sciences	2	2	76
4	Biochemistry	1	1	33
5	Chemical Biology	1	1	33

Steven M. Finegan

Publications

479

Citations

H-Index

Page 1

	Year	Citations
Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa Andrew P. Tomaras, Jared L. Crandon, Craig J. McPherson, Antimicrobial Agents and Chemotherapy	2013	110
Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam Craig J. McPherson, Lisa Aschenbrenner, Brian M. Lacey, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntimicrobial ChemotherapyNo EffectAntibiotic Resistance	2012	89
Preparation, Gram-Negative Antibacterial Activity, and Hydrolytic Stability of Novel Siderophore-Conjugated Monocarbam Diols Mark E. Flanagan, Steven J. Brickner, Manjinder S. Lall, ACS Medicinal Chemistry Letters Bioorganic ChemistryAntimicrobial ChemotherapyPharmaceutical ChemistryDrug ResistanceMedicinal Chemistry	2011	70
Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models D Girard, Steven M. Finegan, Michael W. Dunne, Journal of Antimicrobial Chemotherapy	2005	69
Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections Thomas V. Magee, Sharon L. Ripp, Bryan Li, Journal of Medicinal Chemistry Health SciencesAntibioticsMedicineKlebsiella PneumoniaeMacrolides Addresses Resistance	2009	54
Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV Mark J. Mitton‐Fry, Steven J. Brickner, Judith C. Hamel, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNovel 3-Fluoro-6-methoxyquinoline DerivativesTopoisomerase Iv	2017	33
Cyclic homopentapeptides 1. Analogs of tuberactinomycins and capreomycin with activity against vancomycin-resistant enterococci and Pasteurella John P. Dirlam, ANNETTE M. BELTON, N. C. BIRSNER, Bioorganic & Medicinal Chemistry Letters Antimicrobial SusceptibilityHealth SciencesAntibioticsMedicineVancomycin-resistant Enterococci	1997	22
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections Mark J. Mitton‐Fry, Joel T. Arcari, Matthew F. Brown, Bioorganic & Medicinal Chemistry Letters Gram-negative BacteriologySiderophore Uptake MechanismAntimicrobial SusceptibilityAntibioticsAntibacterial Agent	2012	20
Cyclic homopentapeptides 2. Synthetic modifications of viomycin Joe Lyssikatos, Shang-Poa Chang, J. P. Clancy, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistrySynthetic ModificationsBioorganic ChemistryHeterocyclicNatural Sciences	1997	12

Page 1